
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company. The company focused on the development and commercialization of cell therapies as novel cancer immunotherapy products designed to harness the power of a patient's immune system to eradicate cancer cells. Its lead pipeline can... Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company. The company focused on the development and commercialization of cell therapies as novel cancer immunotherapy products designed to harness the power of a patient's immune system to eradicate cancer cells. Its lead pipeline candidate, LN-145, is an adoptive cell therapy using tumor-infiltrating lymphocytes to treat patients with refractory metastatic melanoma. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.075 | 4.36046511628 | 1.72 | 1.83 | 1.67 | 7932840 | 1.72967032 | CS |
4 | -0.445 | -19.8660714286 | 2.24 | 2.47 | 1.66 | 11064589 | 1.97748353 | CS |
12 | -1.565 | -46.5773809524 | 3.36 | 3.73 | 1.6385 | 13621996 | 2.17781718 | CS |
26 | -5.525 | -75.4781420765 | 7.32 | 7.32 | 1.6385 | 11639602 | 3.28126818 | CS |
52 | -5.555 | -75.5782312925 | 7.35 | 12.505 | 1.6385 | 8942923 | 5.50440793 | CS |
156 | -10.555 | -85.4655870445 | 12.35 | 18.33 | 1.6385 | 6748161 | 7.27296209 | CS |
260 | -28.395 | -94.0543226234 | 30.19 | 54.2081 | 1.6385 | 4942260 | 9.96753455 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.